APYX MEDICAL CORPORATION TO PARTICIPATE IN THE ICR CONFERENCE 2021
CLEARWATER, FL — January 5, 2021 – Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the ICR Conference 2021, which is being held virtually from January 11th-14th. Management will participate in a fireside chat on Thursday, January 14th at 9:15 a.m. Eastern Time.
A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Apyx Medical Corporation investor relations website at https://apyxmedical.com/investor_relations/. An archive of the webcast will be available for replay following the conference.
About Apyx Medical Corporation
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact
Westwicke Partners on behalf of Apyx Medical Corporation
Mike Piccinino, CFA